Clinical trials: Contraceptive Device; Intrauterine
- Condition Contraceptive Device; Intrauterine
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Contraception
Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception
Prospective, multi-center, single-arm, open-label, Phase II clinical study to evaluate the effectiveness, device placement, safety, and tolerability of VeraCept to support commencing a Phase III Clinical Study
- Trial name
- NCT02446821
- Testing
- VeraCept
- Where
- 12 sites in United States
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Sebela Women's Health Inc.
Women at Risk for Pregnancy
A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)
to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women
- Trial name
- IUD (NCT03785366)
- Testing
- VeraCept, ParaGard
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sebela Women's Health Inc.
Women at Risk for Pregnancy
Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS
To assess the contraceptive efficacy (prevention of pregnancy) of VeraCept
- Trial name
- NCT03633799
- Testing
- VeraCept
- Where
- 41 sites in United States
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Sebela Women's Health Inc.
Contraception
Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study
This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel…
- Trial name
- NCT00528112
- Testing
- LCS12, LCS16
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 2,885 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study
The primary objective of this study is to evaluate user satisfaction and tolerability in young women (18-29 years of age) using the LCS12 compared with young women using a COC (Yasmin) over a period of 18 months.
- Trial name
- NCT01254292
- Testing
- Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
- Where
- 94 sites in United States, Austria and 3 more
- Volunteers
- 567 people
- Sponsor
- Bayer
Contraception
Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)
The purpose of this study is to investigate if drug doses lower than the one released from Mirena® would be as effective for contraception as Mirena®.
- Trial name
- NCT00185380
- Testing
- Levonorgestrel IUS (BAY86-5028, G04209B), Levonorgestrel IUS (BAY86-5028, G04209C), Levonorgestrel IUS (Mirena, BAY86-5028)
- Where
- 35 sites in Finland, Hungary and 3 more
- Volunteers
- 742 people
- Sponsor
- Bayer
Menopause
Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).
The study has been designed to look at the transfer from using LNG IUS for contraception only, in reproductive age to using it for endometrial protection in menopausal age.
- Trial name
- NCT00185458
- Testing
- LNG IUS
- Where
- 12 sites in Belgium, Finland and 2 more
- Volunteers
- 394 people
- Sponsor
- Bayer
Contraception
A Study to Evaluate the Safety and Initial Efficacy of a Novel Intrauterine Device
Current intrauterine devices (IUD) pose such risks as uterine perforation during insertion, malposition and expulsion. The investigated device, the IUB(tm) SCu300A is an IUD which is inserted in a similar fashion into the uterus…
- Trial name
- NCT01590563
- Testing
- IUD
- Where
- Hungary
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Ocon Medical Ltd.
Contraception
A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)
The purpose of this study is to demonstrate that a new device inserter leads to successful and safe insertion of Paragard® IUS, comparable to the currently approved IUS inserter, in females of reproductive potential.
- Trial name
- NCT05309694
- Testing
- Paragard® T380A Intrauterine Copper Contraceptive with New Inserter
- Where
- 8 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- CooperSurgical Inc.